New combo aims to stop liver cancer from coming back
NCT ID NCT07352007
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether giving the immunotherapy drug sintilimab along with targeted radiation before surgery can lower the risk of liver cancer returning. About 110 patients with resectable liver cancer will be randomly assigned to receive the combination therapy before surgery or surgery alone. Both groups may also receive sintilimab after surgery for up to a year. The main goal is to see how many patients remain cancer-free after three years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sintilimab (an immunotherapy drug) and stereotactic body radiotherapy (focused radiation)
What this could lead to
If successful, this approach could reduce the chance of liver cancer returning after surgery, potentially improving long-term survival.
What could go wrong
This is a mid-stage trial with only 110 participants, so results may not apply to all patients. The combination therapy may cause side effects like immune reactions or radiation damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ShandongShandong Cancer Hospital and Institute
Jinan, Shandong, China